IOVA - Iovance Biotherapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
3.3B
Enterprise Value 3
2.95B
Trailing P/E
N/A
Forward P/E 1
-15.75
PEG Ratio (5 yr expected) 1
0.88
Price/Sales (ttm)
N/A
Price/Book (mrq)
9.29
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-16.81

Trading Information

Stock Price History

Beta (5Y Monthly) 2.03
52-Week Change 3172.11%
S&P500 52-Week Change 324.46%
52 Week High 326.59
52 Week Low 37.26
50-Day Moving Average 322.83
200-Day Moving Average 321.54

Share Statistics

Avg Vol (3 month) 31.32M
Avg Vol (10 day) 31.2M
Shares Outstanding 5126.19M
Float 103.67M
% Held by Insiders 11.14%
% Held by Institutions 1102.66%
Shares Short (Nov 29, 2019) 415.61M
Short Ratio (Nov 29, 2019) 412.53
Short % of Float (Nov 29, 2019) 413.50%
Short % of Shares Outstanding (Nov 29, 2019) 412.37%
Shares Short (prior month Oct 31, 2019) 414.79M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2100/1
Last Split Date 3Sep 26, 2013

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-33.14%
Return on Equity (ttm)-54.68%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -175.58M
Net Income Avi to Common (ttm)-166.56M
Diluted EPS (ttm)-1.36
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)361.87M
Total Cash Per Share (mrq)2.87
Total Debt (mrq)14.39M
Total Debt/Equity (mrq)4.05
Current Ratio (mrq)10.61
Book Value Per Share (mrq)2.81

Cash Flow Statement

Operating Cash Flow (ttm)-136.62M
Levered Free Cash Flow (ttm)-78.97M